Ryska M
Chirurgická klinika 2. LF UK a UVN Praha.
Rozhl Chir. 2010 Dec;89(12):725-30.
In conjunction with adjuvant chemotherapy, radical resections are the only treatment modality, which significantly prolongs survival in pancreatic cancer (CaP) patients. The author aims to define current standards of radical pancreatic resections in CaP patients and to assess benefits of the surgical procedure based on literature data, as well as to evaluate current options for objective assessment of the quality of life in these patients.
Employing Pubmed and Ebscohost databases, the author compares radical pancreatic resections depending on the tumor location, performed in conjunction with standard lymphadenectomy in patients with CaP, with the extended version of the resection procedure. The radical procedure is then put into relationship with potential prolongation of survival times, with early mortality incidence rates and with rates of perioperative complications. Based on literature data, the author evaluates current options for objective assessment of the quality of life in these patients.
Radical resection with lymphadenectomy in N1-2 diseases followed by adjuvant chemotherapy is currently considered a standard treatment procedure, the only one which significantly prolongs survival in patients with CaP, with the disease stage T1-3, N0-1M0. Angioinvasion into the portomesenteric segment is not a contraindication for the resection procedure. In cases where R0 resection is achieved, the outcomes are similar to those in subjects without vascular segment resections. Views on arterial resections--a. hepatica, truncus coeliacus, a. mesenterica sup. are not uniform and, to date, resections of tumor-infiltrated arteries have not been shown to result in life prolongation. Angioinvasion into arteries is considered a sign of the disease stage and the need for extended procedures is associated with increased complication rates. The quality of life following resection procedures is not commonly assessed and its improvement is usually expected, rather than objectively assessed. At the present time, no questionnaire on the quality of life, which would specifically address CaP patients, is being used on a routine basis.
Radical resection R0 and administration of adjuvant chemotherapy is the only current treatment modality in patients with ductal pancreatic adenocarcinoma, which results in significant life prolongation with 7-25% five-year survival rates (median of 15-18.5 months). The tumor's biological characteristics and the fact that the real disease staging is difficult to establish, are the reasons for early relapses after so called R0 resections. Resections of the portomesenteric segment in cases with adherence or penetration of the CaP into the vascular wall is indicated as a part of the radical PDE and do not result in shorter survival times. Extended radical procedures with arterial resections (a. hepatica, truncus coeliacus, a. mesenterica sup.) do not result in prolonged survival times even in cases where the procedures were assessed as R0 procedures, and cannot be thought of as standard procedures. By using invasive resection procedures, the number of resecable patients would increase, however, the prize of this treatment decision may need to paid off by higher complication rates, compared to those in standard procedures, as well as by lower postoperative quality of life of the patients, while achieving comparable survival time outcomes.
根治性切除术联合辅助化疗是唯一能显著延长胰腺癌(CaP)患者生存期的治疗方式。作者旨在根据文献数据确定CaP患者根治性胰腺切除术的当前标准,评估手术的益处,并评估目前客观评估这些患者生活质量的方法。
作者利用PubMed和Ebscohost数据库,比较了根据肿瘤位置进行的根治性胰腺切除术,这些手术是在CaP患者中与标准淋巴结清扫术联合进行的,以及扩大版的切除手术。然后将根治性手术与生存期的潜在延长、早期死亡率发生率和围手术期并发症发生率联系起来。根据文献数据,作者评估了目前客观评估这些患者生活质量的方法。
N1-2期疾病行根治性切除加淋巴结清扫,随后进行辅助化疗,目前被认为是标准治疗程序,是唯一能显著延长T1-3、N0-1M0期CaP患者生存期的方法。血管侵犯至门静脉肠系膜段并非切除手术的禁忌症。在实现R0切除的情况下,结果与未进行血管段切除的患者相似。关于动脉切除的观点——肝动脉、腹腔干、肠系膜上动脉并不统一,迄今为止,肿瘤浸润动脉的切除尚未显示能延长生存期。血管侵犯至动脉被认为是疾病分期的标志,扩大手术的必要性与并发症发生率增加相关。切除术后的生活质量通常未得到评估,人们通常期望其有所改善,而非进行客观评估。目前,尚无专门针对CaP患者的生活质量问卷被常规使用。
根治性R0切除并给予辅助化疗是目前导管腺癌患者的唯一治疗方式,可显著延长生存期,五年生存率为7%-25%(中位生存期为15-18.5个月)。肿瘤的生物学特性以及难以确定实际疾病分期是所谓R0切除术后早期复发的原因。在CaP粘连或穿透血管壁的情况下,切除门静脉肠系膜段作为根治性胰十二指肠切除术的一部分是必要的,且不会导致生存期缩短。即使在手术被评估为R0手术的情况下,扩大根治性手术(肝动脉、腹腔干、肠系膜上动脉)也不会延长生存期,不能被视为标准手术。通过采用侵入性切除手术,可切除患者的数量会增加,然而,与标准手术相比,这种治疗决策的代价可能是更高的并发症发生率,以及患者术后更低的生活质量,同时生存期结果相当。